The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.

AML Venetoclax Venetoclax/azacitidine combination t-CMML targeted-NGS

Journal

Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512

Informations de publication

Date de publication:
2022
Historique:
received: 03 03 2022
accepted: 15 04 2022
entrez: 26 5 2022
pubmed: 27 5 2022
medline: 27 5 2022
Statut: epublish

Résumé

The addition of Venetoclax (VEN) to Hypomethylating agents (HMAs) significantly improves the probability of complete remission and prolongs survival in patients with Acute Myeloid Leukemia (AML) when compared to HMA alone. However, the mutated clone composition may impact the probability of response and its duration. Here, we describe the molecular profile of a patient with AML rapidly evolved from a previous therapy-related-Chronic MyeloMonocytic Leukemia, who achieved safely complete remission after treatment with the VEN/Azacitidine combination, even in the presence of SARS-COVID-2 infection. The targeted NGS analysis showed that the VEN/AZA combination led to the eradication of the

Identifiants

pubmed: 35615323
doi: 10.4084/MJHID.2022.041
pii: mjhid-14-1-e2022041
pmc: PMC9083951
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e2022041

Déclaration de conflit d'intérêts

Competing interests: The authors declare no conflict of Interest. Competing Interests. MTV received honoraria from Celgene/BMS and Abbvie.

Références

Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Acta Haematol. 2021;144(2):132-145
pubmed: 32392559
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Leukemia. 2013 Apr;27(5):1028-36
pubmed: 23223186
Blood. 2013 Apr 11;121(15):3005-15
pubmed: 23372164
Haematologica. 2014 Apr;99(4):613-9
pubmed: 24688109
Blood. 2016 Sep 8;128(10):1408-17
pubmed: 27385790
Leukemia. 2019 Mar;33(3):785-790
pubmed: 30291338
Blood Cancer J. 2021 Sep 21;11(9):157
pubmed: 34548471
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood Adv. 2021 Dec 28;5(24):5565-5573
pubmed: 34610123
Am J Hematol. 2018 Jan;93(1):65-73
pubmed: 29023992
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
Blood. 2020 Mar 12;135(11):791-803
pubmed: 31932844
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187

Auteurs

Antonio Cristiano (A)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Raffaele Palmieri (R)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Emiliano Fabiani (E)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.

Tiziana Ottone (T)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Mariadomenica Divona (M)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Arianna Savi (A)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Francesco Buccisano (F)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Luca Maurillo (L)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Corrado Tarella (C)

European Institute of Oncology (IEO) and University of Milan, Milan, Italy.

William Arcese (W)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Maria Teresa Voso (MT)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.

Classifications MeSH